BR112017001443A2 - método para fabricação de uma proteína, e, heterodímero. - Google Patents
método para fabricação de uma proteína, e, heterodímero.Info
- Publication number
- BR112017001443A2 BR112017001443A2 BR112017001443A BR112017001443A BR112017001443A2 BR 112017001443 A2 BR112017001443 A2 BR 112017001443A2 BR 112017001443 A BR112017001443 A BR 112017001443A BR 112017001443 A BR112017001443 A BR 112017001443A BR 112017001443 A2 BR112017001443 A2 BR 112017001443A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- ablation
- binding
- substitution
- domain
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 7
- 108090000623 proteins and genes Proteins 0.000 title abstract 7
- 239000000833 heterodimer Substances 0.000 title 1
- 238000002679 ablation Methods 0.000 abstract 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 abstract 2
- 230000003196 chaotropic effect Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000006467 substitution reaction Methods 0.000 abstract 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract 1
- 239000001110 calcium chloride Substances 0.000 abstract 1
- 229910001628 calcium chloride Inorganic materials 0.000 abstract 1
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 239000012149 elution buffer Substances 0.000 abstract 1
- 229910001629 magnesium chloride Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3819—Affinity chromatography of the nucleic acid-nucleic acid binding protein type
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/26—Cation exchangers for chromatographic processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
cromatografia de proteína de alta resolução a empregando um agente caotrópico e uma gradiente de ph ou tampão de eluição de etapa de ph resulta em resolução de pico melhorado entre espécies moleculares estreitamente relacionadas. anticorpos biespecíficos contendo um domínio ch3 de substituição ablação e ligação de proteína a pareado com um domínio ch3 de ligação de proteína a são separados com resolução de alto pico de anticorpos monoespecíficos contendo um domínio ch3 de substituição ablação e ligação de proteína a pareado com o domínio ch3 de substituição ablação e ligação de proteína a e anticorpos monoespecíficos contendo um domínio ch3 de ligação de proteína a pareado com o domínio ch3 de ligação de proteína a. agentes caotrópicos úteis incluem cloreto de magnésio e cloreto de cálcio.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462029463P | 2014-07-26 | 2014-07-26 | |
| US62/029463 | 2014-07-26 | ||
| PCT/US2015/041936 WO2016018740A2 (en) | 2014-07-26 | 2015-07-24 | Purification platform for bispecific antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017001443A2 true BR112017001443A2 (pt) | 2017-12-05 |
| BR112017001443B1 BR112017001443B1 (pt) | 2024-03-26 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY187051A (en) | Purification platform for bispecific antibodies | |
| PH12019500600A1 (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
| PH12018500233A1 (en) | Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof | |
| BR112017020054A2 (pt) | anticorpos para icos | |
| EA201890382A1 (ru) | Конструкции антител для cd70 и cd3 | |
| CO2018000887A2 (es) | Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3 | |
| BR112018001530A2 (pt) | anticorpo biespecífico, polinucleotídeo, vetor, célula hospedeira, métodos para produzir o anticorpo biespecífico e de inibição do crescimento de células tumorais e composição farmacêutica | |
| EA201792226A1 (ru) | Полипептиды, содержащие de novo связывающий домен, и их применение | |
| EA201890337A1 (ru) | Конструкции антитела к flt3 и cd3 | |
| UA120060C2 (uk) | Виділене біспецифічне антитіло до cd123 (il3-r-alpha)хcd3 і його застосування | |
| BR112014028785A2 (pt) | proteínas de ligação a antígeno de st2 | |
| EA201890390A8 (ru) | БИСПЕЦИФИЧЕСКИЕ КОНСТРУКТЫ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ EGFRvIII И CD3 | |
| MX2020006668A (es) | Anticuerpos para lilrb2. | |
| EA201890383A8 (ru) | Конструкции биспецифических антител, связывающиеся с мезотелином и кд3 (cd3) | |
| BR112016024515A2 (pt) | proteínas do agonista do receptor trail de cadeia única | |
| BR112016013347A2 (pt) | anticorpo monoclonal humano neutralizante anti-il-33 | |
| EA201790307A1 (ru) | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки | |
| BR112017013661A2 (pt) | conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica | |
| SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
| BR112018072723A2 (pt) | composição, e, métodos para tratar uma doença em um sujeito e para aumentar uma resposta imunológica em um sujeito | |
| BR112019012796A2 (pt) | proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas | |
| MX2016009877A (es) | Anticuerpos anti-baff novedosos. | |
| BR112017001782A2 (pt) | fragmentos de anticorpo radiomarcados para uso na prevenção e/ou tratamento de câncer | |
| BR112018008799A2 (pt) | método de prognóstico | |
| EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/07/2015, OBSERVADAS AS CONDICOES LEGAIS |